| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T1 |
0-125 |
DRI_Challenge |
denotes |
Matrix metalloproteinase inhibitor KB-R7785 attenuates brain damage resulting from permanent focal cerebral ischemia in mice. |
| T2 |
126-225 |
DRI_Approach |
denotes |
Matrix metalloproteinases (MMPs) are proteolytic enzymes that can degrade the extracellular matrix. |
| T3 |
226-289 |
DRI_Background |
denotes |
MMP-9 and MMP-2 have been implicated in brain injury formation. |
| T4 |
290-432 |
DRI_Background |
denotes |
The authors examined the effect of MMP inhibitor KB-R7785 on brain infarct formation resulting from permanent focal cerebral ischemia in mice. |
| T5 |
433-545 |
DRI_Background |
denotes |
Ischemia was induced by intraluminal middle cerebral artery occlusion (MCAO) in mice under halothane anesthesia. |
| T6 |
546-626 |
DRI_Background |
denotes |
Zymography was conducted to measure the MMPs activity in ischemic brain tissues. |
| T7 |
627-865 |
DRI_Outcome |
denotes |
Injection of KB-R7785 (100 mg/kg) 30 min before MCAO significantly decreased both MMP-9 activity and infarct volume determined at 24 h. In addition, KB-R7785 injected twice at 1 and 4.5 h after MCAO significantly decreased infarct volume. |
| T8 |
866-1050 |
DRI_Outcome |
denotes |
These results indicate that KB-R7785 has a protective efficacy against focal cerebral ischemia, and our data provide further evidence that MMP-9 contributes to brain infarct formation. |
